Sophie He/LinkedIn
Aug 12, 2026, 06:01
Sophie He: Exploring Manufacturing Scalability and Cell Separation
Sophie He, Vice President Cell Therapy, Head of M&A and Partnering at Bracco shared a post on LinkedIn:
“In my latest interview with Technology Networks, I explored a critical but often overlooked bottleneck: manufacturing scalability and cell separation.
Cell and gene therapies have opened the potential to curing once – incurable conditions like sickle cell disease.
But approval is only half the story – the real question is, how many patients actually get treated?
Thank you to Izzy Hirst and Anna-Marie MacDonald at Technology Networks for the great conversation.
Full interview here.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD
-
Sep 29, 2026, 10:49Alison Davey: The Vital Role of Community Support in Bleeding Disorders
-
Sep 29, 2026, 10:36Abdul Muqtadir Abbasi: 5 Questions to Ask When the CBC Is Abnormal
-
Sep 29, 2026, 10:28Manu Morales Sánchez: DOACs in Intermediate Risk Atrial Fibrillation
-
Sep 29, 2026, 09:59William Sauer: Ablation in Patients With LAAO Devices
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia